ClinicalTrials.gg

Program

1 % Bevemipretide

Also written as “2% Bevemipretide”.

Its studies are mostly in Macular Degeneration, led by Mighty Therapeutics.

Furthest: phase 3, since Nov 3, 20261 company-led study, 1 open or runningNext primary completion: Mar 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mighty Therapeutics11 open or runningphase 3since Nov 3, 2026Nov 3, 2026Mar 2029phase 3 · NCT07927010

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 3, 2026First study: phase 3 study in Macular DegenerationFirst studyNCT07927010 · 300 planned

Ahead

  1. Mar 2029Primary completion: phase 3 study in Macular DegenerationNCT07927010

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07927010Macular Degeneration3Not yet recruitingMar 2029300

How it is read

Names in the registry

  • “1 % Bevemipretide”, 1 entry
  • “2% Bevemipretide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.